ANI Pharmaceuticals (NASDAQ:ANIP) Issues Quarterly Earnings Results, Beats Estimates By $0.30 EPS

ANI Pharmaceuticals (NASDAQ:ANIP) issued its earnings results on Friday. The specialty pharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30, Briefing.com reports. The business had revenue of $227.81 million during the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The company’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.34 earnings per share. ANI Pharmaceuticals updated its FY 2025 guidance to 7.370-7.640 EPS.

ANI Pharmaceuticals Trading Up 0.2%

ANI Pharmaceuticals stock traded up $0.20 during mid-day trading on Friday, hitting $90.43. The company’s stock had a trading volume of 710,592 shares, compared to its average volume of 369,356. The stock’s fifty day moving average is $93.58 and its two-hundred day moving average is $77.54. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. The firm has a market capitalization of $1.96 billion, a PE ratio of -117.44 and a beta of 0.54. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $99.50.

Insider Buying and Selling

In related news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Friday, September 19th. The shares were sold at an average price of $98.04, for a total value of $98,040.00. Following the sale, the senior vice president directly owned 60,186 shares in the company, valued at approximately $5,900,635.44. The trade was a 1.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Meredith Cook sold 400 shares of the company’s stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $90.09, for a total transaction of $36,036.00. Following the completion of the transaction, the vice president directly owned 75,674 shares in the company, valued at $6,817,470.66. The trade was a 0.53% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 413,830 shares of company stock valued at $36,505,378. 11.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $28,000. State of Wyoming purchased a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $50,000. Tower Research Capital LLC TRC lifted its stake in ANI Pharmaceuticals by 542.0% during the second quarter. Tower Research Capital LLC TRC now owns 1,727 shares of the specialty pharmaceutical company’s stock worth $113,000 after purchasing an additional 1,458 shares in the last quarter. State of Tennessee Department of Treasury boosted its position in shares of ANI Pharmaceuticals by 54.5% during the second quarter. State of Tennessee Department of Treasury now owns 5,762 shares of the specialty pharmaceutical company’s stock worth $376,000 after buying an additional 2,032 shares during the period. Finally, Canada Pension Plan Investment Board grew its stake in shares of ANI Pharmaceuticals by 90.0% in the second quarter. Canada Pension Plan Investment Board now owns 7,600 shares of the specialty pharmaceutical company’s stock valued at $496,000 after buying an additional 3,600 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ANIP shares. Piper Sandler reissued an “overweight” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 21st. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Weiss Ratings upgraded ANI Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, October 24th. Finally, Guggenheim raised their target price on ANI Pharmaceuticals from $86.00 to $114.00 and gave the stock a “buy” rating in a research note on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $99.14.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.